Folfiri plus cetuximab for advanced, gene-matched colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination chemotherapy (Folfiri) plus cetuximab works better for people with stage IV colorectal cancer that has specific tumor gene markers and a specific blood-gene type. It may help you shrink tumors or control the cancer if you match the study’s required lab and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of colorectal adenocarcinoma (colon/rectal cancer).
- Your tumor test shows KRAS, NRAS, and BRAF are wild-type (not the “mutated” forms the study excludes).
- Your genetic blood type is FcγRIIIa V/V (a specific variant found on blood-genetic testing).
- Your cancer is stage IV and you have at least one measurable tumor spot on scans.
- Your overall health score is ECOG 0 or 1, and you are expected to live more than 3 months.
- Your bloodwork and organ tests are within required limits (white blood cells, platelets, hemoglobin, kidney, and liver/bilirubin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.